{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:53:50Z","timestamp":1776326030258,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":2439,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1111\/ajt.13557","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T13:48:38Z","timestamp":1453124918000},"page":"1266-1275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effect of Treatment With Tabalumab, a B Cell\u2013Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation"],"prefix":"10.1016","volume":"16","author":[{"given":"M.A.","family":"Mujtaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.J.","family":"Komocsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Nantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Samaniego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.","family":"Henson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Hague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Lobashevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.G.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Czader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.K.","family":"Book","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Pescovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.E.","family":"Taber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.13557_bib1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1993.03510110079036","article-title":"Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients","volume":"270","author":"Port","year":"1993","journal-title":"JAMA"},{"key":"10.1111\/ajt.13557_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.01651105","article-title":"Presensitization: The problem and its management","volume":"1","author":"Jordan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/ajt.13557_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198502283120905","article-title":"The quality of life of patients with end-stage renal disease","volume":"312","author":"Evans","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.13557_bib4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/00007890-199210000-00018","article-title":"The quality of life in renal transplantation\u2014A prospective study","volume":"54","author":"Russell","year":"1992","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13557_bib5","first-page":"1","article-title":"OPTN\/SRTR 2013 Annual Data Report: Kidney","volume":"15","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13557_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.humimm.2014.02.024","article-title":"Risk factors of sensitization to human leukocyte antigen in end-stage renal disease patients","volume":"75","author":"Hung","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1111\/ajt.13557_bib7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.13557_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/ajt.13557_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrneph.2010.34","article-title":"Sensitized renal transplant recipients: current protocols and future directions","volume":"6","author":"Gloor","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1111\/ajt.13557_bib10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/TP.0b013e3181d21e7f","article-title":"Use of IVIG plus single dose rituximab for desensitization of highly-HLA sensitized patients awaiting kidney transplantation","volume":"89","author":"Vo","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13557_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1600-6143.2005.01214.x","article-title":"Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients","volume":"6","author":"Jordan","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13557_bib12","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1111\/j.1600-6143.2010.03191.x","article-title":"Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access","volume":"10","author":"Lonze","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13557_bib13","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13557_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/TP.0b013e3182962c84","article-title":"Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab","volume":"96","author":"Lobashevsky","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13557_bib15","doi-asserted-by":"crossref","first-page":"E375","DOI":"10.1111\/ctr.12142","article-title":"The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates","volume":"27","author":"Taber","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.13557_bib16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/ajt.13557_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: A double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/ajt.13557_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"10.1111\/ajt.13557_bib19","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/ajt.13557_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/ajt.13557_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0b013e318298dd65","article-title":"Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection","volume":"96","author":"Banham","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13557_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.TP.0000438211.34842.5e","article-title":"Peripheral B-cell phenotype and BAFF levels are associated with HLA immunization in patients awaiting kidney transplantation","volume":"97","author":"Snanoudj","year":"2014","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13557_bib23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/annrheumdis-2012-202864","article-title":"A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"10.1111\/ajt.13557_bib24","first-page":"1923","article-title":"Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX)","volume":"60","author":"Genovese","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/ajt.13557_bib25","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/00007890-199812270-00014","article-title":"Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System","volume":"66","author":"Ojo","year":"1998","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13557_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/01.tp.0000235434.13327.11","article-title":"Evaluating the survival benefit of kidney retransplantation","volume":"82","author":"Rao","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/ajt.13557_bib27","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.293.15.1883","article-title":"Kidney paired donation and optimizing the use of live donor organs","volume":"293","author":"Segev","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/ajt.13557_bib28","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/eji.200425198","article-title":"BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses","volume":"34","author":"Ye","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1111\/ajt.13557_bib29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/ajt.13045","article-title":"Neutralizing BAFF\/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model","volume":"15","author":"Kwun","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13557_bib30","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1111\/ajt.12974","article-title":"The new kidney allocation system (KAS) and the highly sensitized patient: Expect the unexpected","volume":"14","author":"Bray","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1111\/ajt.13557_bib31","unstructured":"ClinicalTrials.gov A service of the U.S. National Institutes of Health; 2009 [updated Jan 10, 2012; cited Sep 21, 2015]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01025193."},{"key":"10.1111\/ajt.13557_bib32","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.yexcr.2011.02.005","article-title":"BAFF inhibition: a new class of drugs for the treatment of autoimmunity","volume":"317","author":"Liu","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1111\/ajt.13557_bib33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.4049\/jimmunol.1302661","article-title":"B cell depletion curtials CD4+ T cell memory and reduces protection against disseminating virus infection","volume":"192","author":"Misumi","year":"2014","journal-title":"J Immunol"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.13557","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522008917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522008917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:11:42Z","timestamp":1761628302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522008917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1600613522008917"],"URL":"https:\/\/doi.org\/10.1111\/ajt.13557","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Treatment With Tabalumab, a B Cell\u2013Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.13557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}